Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of TP53 and MDM2 polymorphisms with survival in bladder cancer patients treated with chemoradiotherapy.

Cancer science - 1 Dec 2009

Shinohara Asano, Sakano Shigeru, Hinoda Yuji, Nishijima Jun, Kawai Yoshihisa, Misumi Taku, Nagao Kazuhiro, Hara Takahiko, Matsuyama Hideyasu

Abstract excerpt

Platinum-based chemoradiotherapy (CRT) as bladder conservation therapy has shown promising results for muscle-invasive bladder cancer. However, CRT might diminish survival as a result of the delay in cystectomy for some patients with non-responding bladder tumors. Because the p53 tumor suppressio...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aged, 80 and over
Share to Codon

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Polymorphism, Single Nucleotide

Share to Proto-Oncogene Proteins c-mdm2

Share to Tumor Suppressor Protein p53

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 19764997
DOI: 10.1111/j.1349-7006.2009.01331.x
PMCID: PMC11159677

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19764997-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of TP53 and MDM2 polymorphisms with survival in bladder cancer patients treated with chemoradiotherapy.PMID 19764997Read ↗

Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy.Semantic proximity Read ↗

Tp53 and its potential therapeutic role as a target in bladder cancerSemantic proximity Read ↗

Nucleotide excision repair gene polymorphisms may predict acute toxicity in patients treated with chemoradiotherapy for bladder cancer.Semantic proximity Read ↗

The MDM2 SNP309T>G polymorphism increases bladder cancer risk among Caucasians: a meta-analysis.Semantic proximity Read ↗

Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder.Semantic proximity Read ↗

Significance of TP53 mutation in bladder cancer disease progression and drug selectionSemantic proximity Read ↗

p53 and chemosensitivity in bladder cancer.Semantic proximity Read ↗

The T309G murine double minute 2 gene polymorphism is an independent prognostic factor for patients with renal cell carcinoma.Semantic proximity Read ↗

MDM2 T309G polymorphism is associated with bladder cancer.Semantic proximity Read ↗

An updated meta-analysis on the association of MDM2 SNP309 polymorphism with colorectal cancer risk.Semantic proximity Read ↗

Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target.Semantic proximity Read ↗

Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.